Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 202.36$. Average daily volumn in 3 months 1.14M. Market cap 31.58B



Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 215.65$. Total volume : 14.61k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price
215.65$
Change
-0.33
Volume
14.61k

Previous Close215.98
Open213.11
Day Range215.40-215.90
Bid215.10 x 800
Ask220.80 x 900
Volume14.61k
Average Volume1.14M
Market Cap31.58B
Beta0.42
52 Week Range187.16-372.12
Trailing P/E21.87
Foward P/E13.48
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).


Loading ...



Organization

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
31.58B
Revenue:
10.98B
Total Assets:
23.88B
Total Cash:
2.26B


News about "Biogen Inc."

biogen-inc-stock-outperforms-competitors-on-strong-trading-day-image

Biogen Inc. stock outperforms competitors on strong trading day

Source from : MarketWatch - 23 hours ago

Shares of Biogen Inc. advanced 1.60% to $215.98 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P ...See details»


the-petri-dish-fda-to-fast-track-biogens-next-alzheimers-drug-image

The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drug

Source from : The Business Journals - 11 hours ago

The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory ...See details»


biogens-alzheimers-drug-will-get-priority-review-in-us-image

Biogen’s Alzheimer’s drug will get priority review in US

Source from : The Boston Globe - 1 days ago

The Food and Drug Administration accepted the application under the accelerated approval pathway and is expected to complete the review by Jan. 6, the companies said in a statement.See details»


fda-decision-on-eisai-biogen-alzheimers-drug-due-in-january-image

FDA decision on Eisai, Biogen Alzheimer's drug due in January

Source from : Reuters - 1 days ago

The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on ...See details»


biogen-inc-nasdaqbiib-shares-sold-by-wedbush-securities-inc-image

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Wedbush Securities Inc.

Source from : Defense World - 2 days ago

Wedbush Securities Inc. lowered its position in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 27.5% during the first quarter, Holdings Channel reports. The fund owned 1,832 shares of the ...See details»


xponance-inc-acquires-364-shares-of-biogen-inc-nasdaqbiib-image

Xponance Inc. Acquires 364 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : Defense World - 4 days ago

Xponance Inc. grew its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 3.9% in the first quarter, HoldingsChannel reports. The fund owned 9,791 shares of the biotechnology company’s stock after ...See details»


can-biogens-backup-plan-for-alzheimers-succeed-image

Can Biogen’s backup plan for Alzheimer’s succeed?

Source from : The Boston Globe on MSN.com - 3 days ago

Biogen and its partner Eisai have submitted another Alzheimer’s therapy to the FDA. But just as before, experts are divided on the drug.See details»


exclusive-has-biotech-bottomed-nyse-executive-floor-director-says-biogen-and-these-3-stocks-look-poised-to-outperform-image

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform

Source from : Business Insider - 7 days ago

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.See details»


biogen-to-reimburse-employees-who-travel-100-plus-miles-for-abortion-image

Biogen to reimburse employees who travel 100-plus miles for abortion

Source from : The Business Journals - 8 days ago

In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access ...See details»


ritholtz-wealth-management-sells-233-shares-of-biogen-inc-nasdaqbiib-image

Ritholtz Wealth Management Sells 233 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 7 days ago

Ritholtz Wealth Management lowered its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»


Biogen stops clinical trial tracking Aduhelm

Source from : MarketWatch on MSN.com - 13 days ago

Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»


ibm-retirement-fund-trims-stock-position-in-biogen-inc-nasdaqbiib-image

IBM Retirement Fund Trims Stock Position in Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 10 days ago

IBM Retirement Fund lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the ...See details»


Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review

Source from : Seeking Alpha - 1 days ago

The U.S. Food and Drug Administration (FDA) granted priority review to Biogen (BIIB) and Eisai's (ESALY) (ESALF) lecanemab to treat mild cognitive impairment ((MCI)) due ...See details»


pharmalittle-some-scientists-want-more-vertex-crispr-data-biogen-alzheimers-drug-to-get-priority-review-image

Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review

Source from : STAT - 1 days ago

The FDA will expedite its review of Biogen's and Eisai's experimental Alzheimer's drug lecanemab, with a decision due by Jan. 6, 2023, the companies said.See details»